FDA Approves Second Drug for Alzheimer Disease, Despite Safety Concerns
Approval of Leqembi comes after controversial approval in 2021 of Aduhelm, which met with criticism over concerns about that drug's effectiveness, safety, pricing
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.